Fig. 4
From: High expression of SMPD4 promotes liver cancer and is associated with poor prognosis
Drug sensitivity analysis. A-H The boxplots represented the estimated IC50 for Bicalutamide, Dasatinib, Erlotinib, Gefitinib, Imatinib, Lapatinib, Metformin, Parthenolide and Sunitinib in the high- and low-SMPD4 expression groups